Following these results, an early phase-1 study is evaluating the 89Zr-DFO-REGN3767 anti-LAG-3 antibody for PET in R/R DLBCL patients (NCT04566978). This evidence concerns the gene LAG3 and diffuse large B-cell lymphoma.